Porton Pharma Solutions Ltd(300363) march 25 released the performance forecast for the first quarter of 2022. It is estimated that the operating revenue from January to March this year will be 1.357 billion yuan to 1.466 billion yuan, with a year-on-year increase of 150% – 170%; The net profit attributable to the parent company was RMB 326 million to RMB 344 million, with a significant year-on-year increase of 270% – 290%; The net profit after deducting non-profit was 324 million yuan to 339 million yuan, with an increase of 330% – 350%. In the first quarter of 2021, the company realized an operating revenue of 543 million yuan, a net profit attributable to the parent of 88.09 million yuan and a net profit of 75.27 million yuan after deducting non profits.
The company said that thanks to the continued high prosperity of cdmo industry, the company’s customer pipelines and product pipelines were continuously expanded and enriched. During the reporting period, the company’s orders on hand increased strongly, and the major orders received in the early stage were delivered smoothly one after another; At the same time, the company’s profitability was further improved by continuously improving its R & D technology capacity and delivery capacity, and the profit growth exceeded the revenue growth.
Porton Pharma Solutions Ltd(300363) the 2021 annual report released at the same time shows that last year, the company achieved an operating revenue of 3.105 billion yuan, a year-on-year increase of 49.87%; The net profit attributable to the parent company was 524 million yuan, a year-on-year increase of 61.49%; The net profit after deducting non-profit was 503 million yuan, an increase of 74.42%; Earnings per share is 0.97 yuan. The company’s profit distribution plan for the year of 21 is 1.93 yuan (including tax) for 10 dividends.
It is understood that after four years of strategic transformation and upgrading, the company has established a business system covering the three sectors of “API cdmo”, “preparation cdmo” and “gene cell therapy cdmo”, which can provide customers with cdmo services throughout the life cycle of drug development, from preclinical development to clinical trial and then to listing. During the reporting period, the company’s core business segment, API cdmo business, achieved a year-on-year increase of 51%, preparation cdmo business, achieved a breakthrough of “from 0 to 1”, achieved an operating revenue of RMB 2016 million, and gene cell therapy cdmo business, achieved an operating revenue of RMB 13.87 million, a year-on-year increase of 897%. From the perspective of customer location, the European market, as the largest market of the company, achieved a year-on-year increase of 40% in operating revenue; The second and third largest markets are the North American market and the Chinese market respectively, and the operating revenue has increased significantly by 71% and 110% respectively.
Looking forward to 2022, Porton Pharma Solutions Ltd(300363) said that it would fully seize the market opportunities, vigorously invest in the three core competencies of “end-to-end service”, “technology platform” and “excellent project and excellent production operation”, and vigorously accelerate the three growth flywheels of “customer experience”, “capacity and ability” and “customer and project pipeline”. At the same time, we will increase investment in digital intelligence, accelerate the exploration of the most open, innovative and reliable new generation pharmaceutical service platform, and strive to raise the business scale of the whole year to a new level.
